These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 24751443)

  • 1. Discovery of structurally novel, potent and orally efficacious GPR119 agonists.
    Alper P; Azimioara M; Cow C; Mutnick D; Nikulin V; Michellys PY; Wang Z; Reding E; Paliotti M; Li J; Bao D; Zoll J; Kim Y; Zimmerman M; Groessel T; Tuntland T; Joseph SB; McNamara P; Seidel HM; Epple R
    Bioorg Med Chem Lett; 2014 May; 24(10):2383-7. PubMed ID: 24751443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of a novel series of potent and orally bioavailable GPR119 agonists.
    Koshizawa T; Morimoto T; Watanabe G; Watanabe T; Yamasaki N; Sawada Y; Fukuda T; Okuda A; Shibuya K; Ohgiya T
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3249-3253. PubMed ID: 28648463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of pyrazolo[3,4-d]pyrimidine derivatives as GPR119 agonists.
    Gillespie P; Goodnow RA; Saha G; Bose G; Moulik K; Zwingelstein C; Myers M; Conde-Knape K; Pietranico-Cole S; So SS
    Bioorg Med Chem Lett; 2014 Feb; 24(3):949-53. PubMed ID: 24412066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel tricyclic pyrazolopyrimidines as potent and selective GPR119 agonists.
    Azimioara M; Alper P; Cow C; Mutnick D; Nikulin V; Lelais G; Mecom J; McNeill M; Michellys PY; Wang Z; Reding E; Paliotti M; Li J; Bao D; Zoll J; Kim Y; Zimmerman M; Groessl T; Tuntland T; Joseph SB; McNamara P; Seidel HM; Epple R
    Bioorg Med Chem Lett; 2014 Dec; 24(23):5478-83. PubMed ID: 25455488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and biological evaluation of novel 4-amino-2-phenylpyrimidine derivatives as potent and orally active GPR119 agonists.
    Negoro K; Yonetoku Y; Misawa-Mukai H; Hamaguchi W; Maruyama T; Yoshida S; Takeuchi M; Ohta M
    Bioorg Med Chem; 2012 Sep; 20(17):5235-46. PubMed ID: 22836190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
    Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
    Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and structure-activity relationship of fused-pyrimidine derivatives as a series of novel GPR119 agonists.
    Negoro K; Yonetoku Y; Moritomo A; Hayakawa M; Iikubo K; Yoshida S; Takeuchi M; Ohta M
    Bioorg Med Chem; 2012 Nov; 20(21):6442-51. PubMed ID: 23010456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119.
    Semple G; Fioravanti B; Pereira G; Calderon I; Uy J; Choi K; Xiong Y; Ren A; Morgan M; Dave V; Thomsen W; Unett DJ; Xing C; Bossie S; Carroll C; Chu ZL; Grottick AJ; Hauser EK; Leonard J; Jones RM
    J Med Chem; 2008 Sep; 51(17):5172-5. PubMed ID: 18698756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of 6,7-dihydro-5H-pyrrolo[2,3-a]pyrimidines as orally available G protein-coupled receptor 119 agonists.
    Katamreddy SR; Carpenter AJ; Ammala CE; Boros EE; Brashear RL; Briscoe CP; Bullard SR; Caldwell RD; Conlee CR; Croom DK; Hart SM; Heyer DO; Johnson PR; Kashatus JA; Minick DJ; Peckham GE; Ross SA; Roller SG; Samano VA; Sauls HR; Tadepalli SM; Thompson JB; Xu Y; Way JM
    J Med Chem; 2012 Dec; 55(24):10972-94. PubMed ID: 23214471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and SAR studies of bicyclic amine series GPR119 agonists.
    Sakairi M; Kogami M; Torii M; Kataoka H; Fujieda H; Makino M; Kataoka D; Okamoto R; Miyazawa T; Okabe M; Inoue M; Takahashi N; Harada S; Watanabe N
    Bioorg Med Chem Lett; 2012 Aug; 22(15):5123-8. PubMed ID: 22765901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a novel trans-1,4-dioxycyclohexane GPR119 agonist series.
    Han S; Narayanan S; Kim SH; Calderon I; Zhu X; Kawasaki A; Yue D; Lehmann J; Wong A; Buzard DJ; Semple G; Carroll C; Chu ZL; Al-Sharmma H; Shu HH; Tung SF; Unett DJ; Behan DP; Yoon WH; Morgan M; Usmani KA; Chen C; Sadeque A; Leonard JN; Jones RM
    Bioorg Med Chem Lett; 2015 Aug; 25(15):3034-8. PubMed ID: 26048791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and optimization of arylsulfonyl 3-(pyridin-2-yloxy)anilines as novel GPR119 agonists.
    Zhang JK; Li AR; Yu M; Wang Y; Zhu J; Kayser F; Medina JC; Siegler K; Conn M; Shan B; Grillo MP; Eksterowicz J; Coward P; Liu JJ
    Bioorg Med Chem Lett; 2013 Jun; 23(12):3609-13. PubMed ID: 23648181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circumventing seizure activity in a series of G protein coupled receptor 119 (GPR119) agonists.
    Scott JS; Bowker SS; Brocklehurst KJ; Brown HS; Clarke DS; Easter A; Ertan A; Goldberg K; Hudson JA; Kavanagh S; Laber D; Leach AG; MacFaul PA; Martin EA; McKerrecher D; Schofield P; Svensson PH; Teague J
    J Med Chem; 2014 Nov; 57(21):8984-98. PubMed ID: 25286150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of novel pyrimido[5,4-d]pyrimidine derivatives as GPR119 agonist for treatment of type 2 diabetes.
    Fang Y; Xu J; Li Z; Yang Z; Xiong L; Jin Y; Wang Q; Xie S; Zhu W; Chang S
    Bioorg Med Chem; 2018 Aug; 26(14):4080-4087. PubMed ID: 30100020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery, optimisation and in vivo evaluation of novel GPR119 agonists.
    Brocklehurst KJ; Broo A; Butlin RJ; Brown HS; Clarke DS; Davidsson Ö; Goldberg K; Groombridge SD; Kelly EE; Leach A; McKerrecher D; O'Donnell C; Poucher S; Schofield P; Scott JS; Teague J; Westgate L; Wood MJ
    Bioorg Med Chem Lett; 2011 Dec; 21(24):7310-6. PubMed ID: 22061639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AS1907417, a novel GPR119 agonist, as an insulinotropic and β-cell preservative agent for the treatment of type 2 diabetes.
    Yoshida S; Tanaka H; Oshima H; Yamazaki T; Yonetoku Y; Ohishi T; Matsui T; Shibasaki M
    Biochem Biophys Res Commun; 2010 Oct; 400(4):745-51. PubMed ID: 20816753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of a nortropanol derivative as a potent and orally active GPR119 agonist for type 2 diabetes.
    Xia Y; Chackalamannil S; Greenlee WJ; Jayne C; Neustadt B; Stamford A; Vaccaro H; Xu XL; Baker H; O'Neill K; Woods M; Hawes B; Kowalski T
    Bioorg Med Chem Lett; 2011 Jun; 21(11):3290-6. PubMed ID: 21536438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimisation of novel 4, 8-disubstituted dihydropyrimido[5,4-
    Fang Y; Zhang S; Li M; Xiong L; Tu L; Xie S; Jin Y; Liu Y; Yang Z; Liu R
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):50-58. PubMed ID: 31656107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of tetrahydropyridopyrimidine derivatives as dual GPR119 and DPP-4 modulators.
    Fang Y; Zhang S; Wu W; Liu Y; Yang J; Li Y; Li M; Dong H; Jin Y; Liu R; Yang Z
    Bioorg Chem; 2020 Jan; 94():103390. PubMed ID: 31662212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of orally active sulfonylphenyl thieno[3,2-d]pyrimidine derivatives as GPR119 agonists.
    Kim H; Kim M; Oh K; Lee S; Lim S; Lee S; Kim YH; Suh KH; Min KH
    Eur J Med Chem; 2023 Oct; 258():115584. PubMed ID: 37356344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.